FGF21 and obesity disorder: We suppose that treatment with SGLT2i activates starvation-mimicking signalling leading to energy dissipation, including the release of FGF-21, but, in obesity, the extent of this response is limited and not sufficient to counteract the compensatory increase of food intake, thus limiting the drug potential on weight loss.